The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark

The study was performed to evaluate the results of treatment of ovarian carcinoma after the introduction of centralised primary surgery in the County of North Jutland, Denmark. Prospective study of consecutive cases of ovarian cancer undergoing primary surgical treatment at the Gynecologic Oncologic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic oncology 2005-12, Vol.99 (3), p.552-556
Hauptverfasser: Soegaard Andersen, Erik, Knudsen, Aage, Svarrer, Tove, Lund, Bente, Nielsen, Kirsten, Grove, Anni, Tetsche, Mette
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 556
container_issue 3
container_start_page 552
container_title Gynecologic oncology
container_volume 99
creator Soegaard Andersen, Erik
Knudsen, Aage
Svarrer, Tove
Lund, Bente
Nielsen, Kirsten
Grove, Anni
Tetsche, Mette
description The study was performed to evaluate the results of treatment of ovarian carcinoma after the introduction of centralised primary surgery in the County of North Jutland, Denmark. Prospective study of consecutive cases of ovarian cancer undergoing primary surgical treatment at the Gynecologic Oncologic Center after the introduction of centralised primary surgery. Results of treatment recorded up to the date of last examination or death. From 1999 to 2002, 107 patients with primary epithelial ovarian cancer underwent primary surgery at the Gynecologic Oncologic Center, Aalborg. This corresponds to 95.5% of patients with invasive carcinoma in the County of North Jutland. All patients with Stage I to Stage IIIB disease had a complete, macroscopically radical cytoreduction performed. In patients with Stage III and IV invasive tumors, the optimal debulking rate was 79.5%, and, in Stage IIIC and IV, the optimal debulking rate was 78.2%. Intra-operative and post-operative complications were generally few. Post-operative death, defined as death within 30 days after surgery, was observed in 4 cases (3.7%). After primary surgery, platinum-based chemotherapy was given in most cases. For Stage I to IV invasive cancer, the median survival was 46 months. In patients with Stage IIIC and IV disease, the median survival was 32 months. In optimally debulked Stage IIIC and IV disease, the median survival was 41 months. The results indicate a survival benefit after introduction of centralised primary surgery. Compared to existing national and regional data on survival in ovarian cancer, the results indicate an increase in median survival for all stages of approximately 15 months. Centralisation of primary surgery to centres with the necessary expertise may be the most significant way to increase survival in ovarian cancer in Denmark.
doi_str_mv 10.1016/j.ygyno.2005.07.121
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68833931</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0090825805006104</els_id><sourcerecordid>68833931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-ad50ed690fd5faae79f6da2162e7fd3b3140ee595e86967185f5592f1d7522de3</originalsourceid><addsrcrecordid>eNp9kM2OFCEURonROD2jT2BiWLmyygsMVLFwYUbHn0w0MeOaMMVlmraqaIGapLc-ubRdiTs3EJLzfdx7CHnBoGXA1Jtde7g_zLHlALKFrmWcPSIbBlo2qpf6MdkAaGh6Lvszcp7zDgAEMP6UnDHFJFz2sCG_b7dIE-ZlLJlGT0tCWyacy_GB-1C2OAY70vhgU7AzHew8YKLWl3oOlUt2DNmWEOdjYp_CZNOB5iXdYzq09Pta7VOc6NeYypZ-WcpoZ_eavse5wj-fkSfejhmfr_cF-XH94fbqU3Pz7ePnq3c3zSBkVxrrJKBTGryT3lrstFfOcqY4dt6JO8EuAVFqib3SqmO99FJq7pnrJOcOxQV5derdp_hrwVzMFPKAYx0G45KN6nshtGAVFCdwSDHnhN6saxkG5qje7Mxf9eao3kBnqvqaernWL3cTun-Z1XUF3p4ArEs-BEwmDwGrThcSDsW4GP77wR_mIZkp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68833931</pqid></control><display><type>article</type><title>The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Soegaard Andersen, Erik ; Knudsen, Aage ; Svarrer, Tove ; Lund, Bente ; Nielsen, Kirsten ; Grove, Anni ; Tetsche, Mette</creator><creatorcontrib>Soegaard Andersen, Erik ; Knudsen, Aage ; Svarrer, Tove ; Lund, Bente ; Nielsen, Kirsten ; Grove, Anni ; Tetsche, Mette</creatorcontrib><description>The study was performed to evaluate the results of treatment of ovarian carcinoma after the introduction of centralised primary surgery in the County of North Jutland, Denmark. Prospective study of consecutive cases of ovarian cancer undergoing primary surgical treatment at the Gynecologic Oncologic Center after the introduction of centralised primary surgery. Results of treatment recorded up to the date of last examination or death. From 1999 to 2002, 107 patients with primary epithelial ovarian cancer underwent primary surgery at the Gynecologic Oncologic Center, Aalborg. This corresponds to 95.5% of patients with invasive carcinoma in the County of North Jutland. All patients with Stage I to Stage IIIB disease had a complete, macroscopically radical cytoreduction performed. In patients with Stage III and IV invasive tumors, the optimal debulking rate was 79.5%, and, in Stage IIIC and IV, the optimal debulking rate was 78.2%. Intra-operative and post-operative complications were generally few. Post-operative death, defined as death within 30 days after surgery, was observed in 4 cases (3.7%). After primary surgery, platinum-based chemotherapy was given in most cases. For Stage I to IV invasive cancer, the median survival was 46 months. In patients with Stage IIIC and IV disease, the median survival was 32 months. In optimally debulked Stage IIIC and IV disease, the median survival was 41 months. The results indicate a survival benefit after introduction of centralised primary surgery. Compared to existing national and regional data on survival in ovarian cancer, the results indicate an increase in median survival for all stages of approximately 15 months. Centralisation of primary surgery to centres with the necessary expertise may be the most significant way to increase survival in ovarian cancer in Denmark.</description><identifier>ISSN: 0090-8258</identifier><identifier>EISSN: 1095-6859</identifier><identifier>DOI: 10.1016/j.ygyno.2005.07.121</identifier><identifier>PMID: 16150480</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Busulfan - analogs &amp; derivatives ; Busulfan - therapeutic use ; Carboplatin - administration &amp; dosage ; Carboplatin - therapeutic use ; Centralisation ; Combined Modality Therapy ; Denmark ; Epithelial Cells - pathology ; Epithelial ovarian cancer ; Female ; Humans ; Middle Aged ; Neoplasm Staging ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - surgery ; Paclitaxel - administration &amp; dosage ; Primary surgery ; Prospective Studies ; Survival Rate ; Treatment Outcome</subject><ispartof>Gynecologic oncology, 2005-12, Vol.99 (3), p.552-556</ispartof><rights>2005 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-ad50ed690fd5faae79f6da2162e7fd3b3140ee595e86967185f5592f1d7522de3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0090825805006104$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16150480$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Soegaard Andersen, Erik</creatorcontrib><creatorcontrib>Knudsen, Aage</creatorcontrib><creatorcontrib>Svarrer, Tove</creatorcontrib><creatorcontrib>Lund, Bente</creatorcontrib><creatorcontrib>Nielsen, Kirsten</creatorcontrib><creatorcontrib>Grove, Anni</creatorcontrib><creatorcontrib>Tetsche, Mette</creatorcontrib><title>The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark</title><title>Gynecologic oncology</title><addtitle>Gynecol Oncol</addtitle><description>The study was performed to evaluate the results of treatment of ovarian carcinoma after the introduction of centralised primary surgery in the County of North Jutland, Denmark. Prospective study of consecutive cases of ovarian cancer undergoing primary surgical treatment at the Gynecologic Oncologic Center after the introduction of centralised primary surgery. Results of treatment recorded up to the date of last examination or death. From 1999 to 2002, 107 patients with primary epithelial ovarian cancer underwent primary surgery at the Gynecologic Oncologic Center, Aalborg. This corresponds to 95.5% of patients with invasive carcinoma in the County of North Jutland. All patients with Stage I to Stage IIIB disease had a complete, macroscopically radical cytoreduction performed. In patients with Stage III and IV invasive tumors, the optimal debulking rate was 79.5%, and, in Stage IIIC and IV, the optimal debulking rate was 78.2%. Intra-operative and post-operative complications were generally few. Post-operative death, defined as death within 30 days after surgery, was observed in 4 cases (3.7%). After primary surgery, platinum-based chemotherapy was given in most cases. For Stage I to IV invasive cancer, the median survival was 46 months. In patients with Stage IIIC and IV disease, the median survival was 32 months. In optimally debulked Stage IIIC and IV disease, the median survival was 41 months. The results indicate a survival benefit after introduction of centralised primary surgery. Compared to existing national and regional data on survival in ovarian cancer, the results indicate an increase in median survival for all stages of approximately 15 months. Centralisation of primary surgery to centres with the necessary expertise may be the most significant way to increase survival in ovarian cancer in Denmark.</description><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Busulfan - analogs &amp; derivatives</subject><subject>Busulfan - therapeutic use</subject><subject>Carboplatin - administration &amp; dosage</subject><subject>Carboplatin - therapeutic use</subject><subject>Centralisation</subject><subject>Combined Modality Therapy</subject><subject>Denmark</subject><subject>Epithelial Cells - pathology</subject><subject>Epithelial ovarian cancer</subject><subject>Female</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Paclitaxel - administration &amp; dosage</subject><subject>Primary surgery</subject><subject>Prospective Studies</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>0090-8258</issn><issn>1095-6859</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM2OFCEURonROD2jT2BiWLmyygsMVLFwYUbHn0w0MeOaMMVlmraqaIGapLc-ubRdiTs3EJLzfdx7CHnBoGXA1Jtde7g_zLHlALKFrmWcPSIbBlo2qpf6MdkAaGh6Lvszcp7zDgAEMP6UnDHFJFz2sCG_b7dIE-ZlLJlGT0tCWyacy_GB-1C2OAY70vhgU7AzHew8YKLWl3oOlUt2DNmWEOdjYp_CZNOB5iXdYzq09Pta7VOc6NeYypZ-WcpoZ_eavse5wj-fkSfejhmfr_cF-XH94fbqU3Pz7ePnq3c3zSBkVxrrJKBTGryT3lrstFfOcqY4dt6JO8EuAVFqib3SqmO99FJq7pnrJOcOxQV5derdp_hrwVzMFPKAYx0G45KN6nshtGAVFCdwSDHnhN6saxkG5qje7Mxf9eao3kBnqvqaernWL3cTun-Z1XUF3p4ArEs-BEwmDwGrThcSDsW4GP77wR_mIZkp</recordid><startdate>20051201</startdate><enddate>20051201</enddate><creator>Soegaard Andersen, Erik</creator><creator>Knudsen, Aage</creator><creator>Svarrer, Tove</creator><creator>Lund, Bente</creator><creator>Nielsen, Kirsten</creator><creator>Grove, Anni</creator><creator>Tetsche, Mette</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20051201</creationdate><title>The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark</title><author>Soegaard Andersen, Erik ; Knudsen, Aage ; Svarrer, Tove ; Lund, Bente ; Nielsen, Kirsten ; Grove, Anni ; Tetsche, Mette</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-ad50ed690fd5faae79f6da2162e7fd3b3140ee595e86967185f5592f1d7522de3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Busulfan - analogs &amp; derivatives</topic><topic>Busulfan - therapeutic use</topic><topic>Carboplatin - administration &amp; dosage</topic><topic>Carboplatin - therapeutic use</topic><topic>Centralisation</topic><topic>Combined Modality Therapy</topic><topic>Denmark</topic><topic>Epithelial Cells - pathology</topic><topic>Epithelial ovarian cancer</topic><topic>Female</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Paclitaxel - administration &amp; dosage</topic><topic>Primary surgery</topic><topic>Prospective Studies</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Soegaard Andersen, Erik</creatorcontrib><creatorcontrib>Knudsen, Aage</creatorcontrib><creatorcontrib>Svarrer, Tove</creatorcontrib><creatorcontrib>Lund, Bente</creatorcontrib><creatorcontrib>Nielsen, Kirsten</creatorcontrib><creatorcontrib>Grove, Anni</creatorcontrib><creatorcontrib>Tetsche, Mette</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Gynecologic oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Soegaard Andersen, Erik</au><au>Knudsen, Aage</au><au>Svarrer, Tove</au><au>Lund, Bente</au><au>Nielsen, Kirsten</au><au>Grove, Anni</au><au>Tetsche, Mette</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark</atitle><jtitle>Gynecologic oncology</jtitle><addtitle>Gynecol Oncol</addtitle><date>2005-12-01</date><risdate>2005</risdate><volume>99</volume><issue>3</issue><spage>552</spage><epage>556</epage><pages>552-556</pages><issn>0090-8258</issn><eissn>1095-6859</eissn><abstract>The study was performed to evaluate the results of treatment of ovarian carcinoma after the introduction of centralised primary surgery in the County of North Jutland, Denmark. Prospective study of consecutive cases of ovarian cancer undergoing primary surgical treatment at the Gynecologic Oncologic Center after the introduction of centralised primary surgery. Results of treatment recorded up to the date of last examination or death. From 1999 to 2002, 107 patients with primary epithelial ovarian cancer underwent primary surgery at the Gynecologic Oncologic Center, Aalborg. This corresponds to 95.5% of patients with invasive carcinoma in the County of North Jutland. All patients with Stage I to Stage IIIB disease had a complete, macroscopically radical cytoreduction performed. In patients with Stage III and IV invasive tumors, the optimal debulking rate was 79.5%, and, in Stage IIIC and IV, the optimal debulking rate was 78.2%. Intra-operative and post-operative complications were generally few. Post-operative death, defined as death within 30 days after surgery, was observed in 4 cases (3.7%). After primary surgery, platinum-based chemotherapy was given in most cases. For Stage I to IV invasive cancer, the median survival was 46 months. In patients with Stage IIIC and IV disease, the median survival was 32 months. In optimally debulked Stage IIIC and IV disease, the median survival was 41 months. The results indicate a survival benefit after introduction of centralised primary surgery. Compared to existing national and regional data on survival in ovarian cancer, the results indicate an increase in median survival for all stages of approximately 15 months. Centralisation of primary surgery to centres with the necessary expertise may be the most significant way to increase survival in ovarian cancer in Denmark.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>16150480</pmid><doi>10.1016/j.ygyno.2005.07.121</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-8258
ispartof Gynecologic oncology, 2005-12, Vol.99 (3), p.552-556
issn 0090-8258
1095-6859
language eng
recordid cdi_proquest_miscellaneous_68833931
source MEDLINE; Elsevier ScienceDirect Journals
subjects Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Busulfan - analogs & derivatives
Busulfan - therapeutic use
Carboplatin - administration & dosage
Carboplatin - therapeutic use
Centralisation
Combined Modality Therapy
Denmark
Epithelial Cells - pathology
Epithelial ovarian cancer
Female
Humans
Middle Aged
Neoplasm Staging
Ovarian Neoplasms - drug therapy
Ovarian Neoplasms - pathology
Ovarian Neoplasms - surgery
Paclitaxel - administration & dosage
Primary surgery
Prospective Studies
Survival Rate
Treatment Outcome
title The results of treatment of epithelial ovarian cancer after centralisation of primary surgery. Results from North Jutland, Denmark
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T17%3A00%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20results%20of%20treatment%20of%20epithelial%20ovarian%20cancer%20after%20centralisation%20of%20primary%20surgery.%20Results%20from%20North%20Jutland,%20Denmark&rft.jtitle=Gynecologic%20oncology&rft.au=Soegaard%20Andersen,%20Erik&rft.date=2005-12-01&rft.volume=99&rft.issue=3&rft.spage=552&rft.epage=556&rft.pages=552-556&rft.issn=0090-8258&rft.eissn=1095-6859&rft_id=info:doi/10.1016/j.ygyno.2005.07.121&rft_dat=%3Cproquest_cross%3E68833931%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68833931&rft_id=info:pmid/16150480&rft_els_id=S0090825805006104&rfr_iscdi=true